Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pemetrexed in Patients With Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00427466
Recruitment Status : Completed
First Posted : January 29, 2007
Last Update Posted : February 16, 2009
Arbeitsgemeinschaft fur Internistische Onkologie
German Sarcoma Group
Information provided by:
University Hospital Tuebingen

Brief Summary:
The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-based chemotherapy and to assess the toxicity profile

Condition or disease Intervention/treatment Phase
Sarcoma Drug: Pemetrexed Phase 2

Detailed Description:
One therapy cycle takes a total of 3 weeks. On day 1, Pemetrexed is intravenously administered. The dosage is 500 mg/m2 over a period of 10 minutes. A repetition of this procedure is performed on day 22

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Phase II Study With Pemetrexed in Patients With Pre-Treated Metastatic Soft Tissue Sarcomas
Study Start Date : January 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Rate of response

Secondary Outcome Measures :
  1. Rate of patients who are progression free at 3 and 6 months
  2. Changes in median period of survival
  3. Progression free survival
  4. Toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed metastasized or locally inoperable soft tissue sarcoma
  • Progression or relapse after previous cytostatic treatment with adriamycin and/or an ifosfamide containing chemotherapeutic substance
  • Two-dimensionally measurable/evaluable tumor parameters (according to WHO-criteria)
  • Previous radiotherapy is acceptable as long as the irradiated area does not include the only measurable lesion
  • Patient compliance and geographic proximity, which ensure the possibility of adequate Follow-up
  • Life expectancy of more than 3 months
  • ECOG <= 2
  • Age at least 18 years
  • Adequate bone marrow function at the initiation of therapy
  • Adequate kidney function
  • Patient consent
  • Patient ability to consent

Exclusion Criteria:

  • Previous or concurrent irradiation of the indicator lesion
  • Other concomitant tumor therapy
  • Severe impairment in hepatic function
  • Active Infection
  • Previous treatment with Pemetrexed
  • Second tumor within the past 5 years (excepting basal cell carcinoma, adequately treated carcinoma in situ of the uterine cervix, of the bladder urothelium or colon polyps including pTis and pTin)
  • Severely symptomatic cardiovascular and cerebrovascular disease
  • HIV, active Hepatitis B or C
  • Dementia, Cerebral stroke with cognitive deficits
  • Kidney function <= 79 ml/min (calculated according to MDRD): Inability to interrupt treatment with NSAIDs/ASS/Cox-2 Inhibitors 2 days prior to and following administration of Pemetrexed. If a patient is taking an NSAID or salicylate with a long half-life it should not be taken five days prior to, on the day of or two days after application of Pemetrexed. Low dose acetyl salicylic acid administration is permitted (e.g. 100 mg/die.) There are no restrictions with kidney function greater than 80 ml/min.
  • Inability or unwillingness to take folic acid, vitamin B12 or dexamethasone
  • Pleural or pericardial exudate, ascites without a drain (3rd Space)
  • Time Interval from the last course of chemotherapy < 4 weeks
  • Symptomatic CNS-Metastases
  • Gravidity or Lactation
  • Women of reproductive age without reliable contraception if not the following applies: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen during and for 3 months after treatment
  • Positive serum or urine pregnancy test
  • Participation in another trial at the same time

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00427466

Layout table for location information
Medical Center II, University of Tuebingen
Tuebingen, Germany, 72076
Sponsors and Collaborators
University Hospital Tuebingen
Arbeitsgemeinschaft fur Internistische Onkologie
German Sarcoma Group
Layout table for investigator information
Principal Investigator: Joerg T Hartmann, MD Medical Center II, University of Tuebingen, Germany
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00427466    
Other Study ID Numbers: jth_006
First Posted: January 29, 2007    Key Record Dates
Last Update Posted: February 16, 2009
Last Verified: February 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors